Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pseudoephedrine + triprolidine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kofed is a fixed-dose combination drug product containing the first-generation antihistamine triprolidine and the nasal decongestant pseudoephedrine. Originally developed by Burroughs Wellcome (now GSK) under the brand name Actifed, Kofed is manufactured as a generic product by Laboratory & Allied in Kenya. It is indicated for the temporary, symptomatic relief of upper respiratory tract symptoms associated with the common cold, allergic rhinitis, and sinusitis. Triprolidine acts as a competitive antagonist of the histamine H1 receptor, reducing allergy-mediated symptoms such as sneezing, rhinorrhea, and watery eyes. Pseudoephedrine acts as a sympathomimetic agonist on alpha- and beta-adrenergic receptors, causing vasoconstriction in the nasal mucosa to relieve nasal and sinus congestion.
- Brand names
- ActifedActifedrinAllerfrimAprodineColdifedED A-HISTFLU-CAREFedrilGenacHistafedHistarhineInistonKofedMaxifed TRNeocoldRinofedSedofanSilafedSudafed Sinus NighttimeTrifedTripofedTri-SudoUnifedZymine-D
- Other names
- pseudoephedrine hydrochloride + triprolidine hydrochloridetriprolidine + pseudoephedrinetriprolidine hydrochloride + pseudoephedrine hydrochloride
02
Targets
NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)ADRA2A (α2A)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on pseudoephedrine + triprolidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pseudoephedrine + triprolidine.